Date: 27-02-2026

To,
The General Manager,
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai – 400001

To,
Manager – Listing,
Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Mumbai — 400051

Ref: Scrip Code at BSE: 533259 and NSE: SASTASUNDR

Sub: Disclosure under Regulation 30A of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), read with Schedule III of the SEBI Listing Regulations, it is hereby informed that the board of directors of Health X Platform Limited (formerly Sastasundar Ventures Limited) ("Company" or "HealthX") have approved the execution of an agreement ("Tripartite Agreement") by the Company with Sastasundar Healthbuddy Limited, its material subsidiary ("SHBL"), and Envision India Fund ("Envision"), a qualified institutional buyer, having registration number GB20025232, incorporated under the laws of Mauritius, having its registered office/office at 6th Floor, Two Tribeca, Tribeca Central, Trianon 72261.

The Tripartite Agreement is being executed pursuant to a share purchase agreement dated 25.02.2026 ("SPA"), entered into between Envision, SHBL and Mitsubishi Corporation, a company incorporated under the laws of Japan and having its registered office at 3-1, Marunouchi 2-Chome, Chiyoda-Ku, Tokyo 100-8086, Japan ("Mitsubishi"), whereby Envision has agreed to acquire the entire shareholding of Mitsubishi in SHBL. It may be pertinent to note that the Company has already made a disclosure regarding the execution of an SPA by SHBL on 25.02.2026 to the stock exchanges.

The Tripartite Agreement contemplates the merger of SHBL with the Company such that the economic interest of Envision in the Company post-merger remains the same as it was in SHBL prior to the merger, subject to the same being in compliance with applicable laws. It is also agreed in the Tripartite Agreement that, if the merger cannot be consummated, the Company shall undertake a share swap arrangement so as to ensure that Envision receives equivalent shares of HealthX in lieu of shares held in SHBL. The Tripartite Agreement also grants Envision a right to appoint director on the Board of the Company in certain circumstances.

Further, the information as required to be disclosed under SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is provided in **Annexure I**.

This is for your information and record.

Yours faithfully,
For Health X Platform Limited
(formerly known as Sastasundar Ventures Limited)

PRATAP SINGH

Digitally signed by PRATAP SINGH
DN: c=IN, o=PERSONAL, title=9767, 2.5.4.20=2a7ee0833f15369050bcb8812721eedc37eb2d96f496ca0b6966de9c83d533a7, postalCode=711204, st=West Bengal, serialNumber=6a38acf8d61293d955d818b2d95dba95f63a20725f3d90094dec69f93829ad46, cn=PRATAP SINGH
Date: 2026.02.27 17:08:08 +05'30'

Pratap Singh
Company Secretary & Compliance Officer
M. No. A24081

ANNEXURE – I

Sl. No.	Particulars	Disclosure
a)	If the listed entity is a party to the agreement, i. details of the counterparties (including name and relationship with the listed entity).	Health X Platform Limited (formerly Sastasundar Ventures Limited), (HealthX or Company) is the party of the Agreement which has been entered into with the following: (i) Sastasundar Healthbuddy Limited (SHBL), material subsidiary of the Company and (ii) Envision India Fund, a qualified institutional buyer, who shall become a shareholder of SHBL, upon completion/ consummation of the purchase of Sastasundar Healthbuddy Limited's shares as contemplated in the SPA.
b)	If the listed entity is not a party to the agreement: i) name of the party entering into such an agreement and the relationship with the listed entity; ii) details of the counterparties to the agreement (including name and relationship with the listed entity); iii) date of entering into the agreement.	Not Applicable, as the Company is the party to the agreement.
c)	Purpose of entering into the agreement	The parties have entered into this Agreement for the purposes of recording the terms and conditions governing the relationship of the shareholders of SHBL, material subsidiary of the Company post Envision becoming a shareholder of SHBL.
d)	shareholding, if any, in the entity with whom the agreement is executed	SHBL is the material subsidiary of the Company and Envision India Fund is the Qualified Institutional Buyer and an Independent Investor. Shareholding of SHBL, post completion of transaction is as following: Health X Platform Limited (formerly known as Sastasundar Ventures Limited) – 17,100,160 Eq. shares Rohto Pharmaceuticals Co., Ltd. – 3,562,064 Eq. shares Envision India Fund - 10,13,766 Eq. shares Total - 21,675,990 Eq. shares
e)	significant terms of the agreement (in brief)	The Tripartite Agreement, contemplates a scheme of arrangement to be undertaken between the Company and SHBL, whereby SHBL shall ultimately be merged with HealthX subject to compliance with Applicable laws.

Sl. No.	Particulars	Disclosure
		The Tripartite Agreement contemplates that the merger shall, subject to compliance with applicable laws, be undertaken in a manner such that the economic interest of Envision in HealthX after the consummation of the scheme shall remain the same as it was in SHBL prior to the merger. It is also agreed in the Tripartite Agreement that, if the scheme of arrangement resulting in merger of SHBL with the Company is not consummated, the Company shall undertake a share swap arrangement so as to ensure that Envision receives equivalent shares of HealthX in lieu of shares held in SHBL. The Board had made a disclosure regarding in-principle approval for undertaking a scheme of arrangement involving merger of SHBL with the Company on 26.02.2026 to the stock exchanges. Envision is also entitled to nominate one director on the board of HealthX in case of any material breach or non-consummation of the merger.
f)	extent and the nature of impact on management or control of the listed entity.	It has been agreed between the parties that this Agreement, contemplates a scheme of arrangement to be undertaken between the Company and SHBL, whereby SHBL shall ultimately be merged with HealthX subject to compliance with Applicable laws. In case, if the scheme of arrangement resulting in merger of SHBL with the Company is not consummated, the Company shall undertake a share swap arrangement so as to ensure that Envision receives equivalent shares of HealthX in lieu of shares held in SHBL. It has also been agreed between the parties to the Tripartite Agreement that Envision is entitled to nominate one director on the board of HealthX in case of any material breach or non-consummation of the merger.
g)	details and quantification of the restriction or liability imposed upon the listed entity.	Same as provided in significant terms and extent and nature of impact on management or control, as listed above.
h)	whether, the said parties are related to promoter/ promoter group/ group companies in any manner. If yes, nature of relationship.	The Company (HealthX) is a promoter of SHBL.
i)	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length".	The transaction falls within the scope of related party transactions as SHBL is material subsidiary of HealthX.

Sl. No.	Particulars	Disclosure
j)	In case of issuance of shares to the parties, details of issue price, class of shares issued.	Not Applicable
k)	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	Not Applicable
l)	In case of rescission, amendment or alteration, listed entity shall disclose additional details to the stock exchange(s): i. name of parties to the agreement; ii. nature of the agreement; iii. date of execution of the agreement; iv. details and reasons for amendment or alteration and impact thereof (including impact on management or control and on the restriction or liability quantified earlier) v. reasons for rescission and impact thereof (including impact on management or control and on the restriction or liability quantified earlier).	Not Applicable

PRATAP SINGH

Digitally signed by PRATAP SINGH
DN: c=IN, o=PERSONAL, title=9767, 2.5.4.20=2a7ee0833f15369050bcb8812721eedc37eb2d96f496ca0b6966de9c83d533a7, postalCode=711204, st=West Bengal, serialNumber=6a38acf8d61293d955d818b2d95dba95f63a20725f3d90094dec69f93829ad46, cn=PRATAP SINGH
Date: 2026.02.27 17:08:34 +05'30'

Date: 27-02-2026

To,
The General Manager,
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai - 400001

To,
Manager – Listing,
Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Mumbai - 400051

Ref: Scrip Code at BSE: 533259 and NSE: SASTASUNDR

Sub: Disclosure under Regulation 30(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Intimation by Sastasundar Healthbuddy Limited ("SHBL"), material subsidiary of the Company, regarding Outcome of its Board Meeting.

Dear Sir/ Madam,

Pursuant to regulation 30(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 ("SEBI Listing Regulations"), it is hereby informed that the board of directors of the Sastasundar Healthbuddy Limited ("SHBL"), material subsidiary of the Health X Platform Limited (formerly Sastasundar Ventures Limited) ("Company" or "HealthX") at its meeting held today has approved the execution of a Agreement ("Tripartite Agreement") by SHBL with the Company, and Envision India Fund ("Envision"), a qualified institutional buyer, having registration number GB20025232, incorporated under the laws of Mauritius, having its registered office/office at 6th Floor, Two Tribeca, Tribeca Central, Trianon 72261 Mauritius.

The Tripartite Agreement is being executed pursuant to a share purchase agreement dated 25.02.2026 ("SPA"), entered into between Envision, SHBL and Mitsubishi Corporation, a company incorporated under the laws of Japan and having its registered office at 3-1, Marunouchi 2-Chome, Chiyoda-Ku, Tokyo 100-8086, Japan ("Mitsubishi"), whereby Envision has agreed to acquire the entire shareholding of Mitsubishi in SHBL. It may be pertinent to note that the Company has already made a disclosure regarding the execution of an SPA by SHBL on 25.02.2026 to the stock exchanges.

The Tripartite Agreement contemplates the merger of SHBL with the Company such that the economic interest of Envision in the Company post-merger remains the same as it was in SHBL prior to the merger, subject to the same being in compliance with applicable laws. It is also agreed in the Tripartite Agreement that, if the merger cannot be consummated, SHBL shall undertake a share swap arrangement so as to ensure that Envision receives equivalent shares of HealthX in lieu of shares held in SHBL. The Tripartite Agreement grants Envision the right to appoint a board observer in a non-voting capacity to the Board of SHBL and also grants Envision the right to appoint a director to the Board of SHBL in certain circumstances.

The Company received the aforesaid information from SHBL on February 27, 2026 at 2:04 PM. This is for your information and record.

Yours faithfully,
For Health X Platform Limited
(formerly known as Sastasundar Ventures Limited)

PRATAP SINGH

Digitally signed by PRATAP SINGH
DN: c=IN, o=PERSONAL, title=9767, 2.5.4.20=2a7ee0833f153690505bcb8812721eedc37eb2d86f496ca0b6966de9c83d5533a7, postalCode=711204, st=West Bengal, serialNumber=6a38ac8b061293d955c0818b2d0f5dba95f653a20725f3d90094dac669f938293ad46, cn=PRATAP SINGH
Date: 2026.02.27 16:35:05 +05'30'

Pratap Singh
Company Secretary & Compliance Officer
M. No. A24081

Date: 27-02-2026

To,
The General Manager,
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai – 400001

To,
Manager – Listing,
Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Mumbai — 400051

Ref: Scrip Code at BSE: 533259 and NSE: SASTASUNDR

Sub: Disclosure under Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Outcome of Meeting of the Board of Directors

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), read with Schedule III of the SEBI Listing Regulations, it is hereby informed that the board of directors of Health X Platform Limited (formerly Sastasundar Ventures Limited) ("Company" or "HealthX") at its meeting held today have approved the execution of an agreement ("Tripartite Agreement") by the Company with Sastasundar Healthbuddy Limited, its material subsidiary ("SHBL"), and Envision India Fund ("Envision"), a qualified institutional buyer, having registration number GB20025232, incorporated under the laws of Mauritius, having its registered office/office at 6th Floor, Two Tribeca, Tribeca Central, Trianon 72261.

The Tripartite Agreement is being executed pursuant to a share purchase agreement dated 25.02.2026 ("SPA"), entered into between Envision, SHBL and Mitsubishi Corporation, a company incorporated under the laws of Japan and having its registered office at 3-1, Marunouchi 2-Chome, Chiyoda-Ku, Tokyo 100-8086, Japan ("Mitsubishi"), whereby Envision has agreed to acquire the entire shareholding of Mitsubishi in SHBL. It may be pertinent to note that the Company has already made a disclosure regarding the execution of an SPA by SHBL on 25.02.2026 to the stock exchanges.

The Tripartite Agreement contemplates the merger of SHBL with the Company such that the economic interest of Envision in the Company post-merger remains the same as it was in SHBL prior to the merger, subject to the same being in compliance with applicable laws. It is also agreed in the Tripartite Agreement that, if the merger cannot be consummated, the Company shall undertake a share swap arrangement so as to ensure that Envision receives equivalent shares of HealthX in lieu of shares held in SHBL. The Tripartite Agreement also grants Envision a right to appoint director on the Board of the Company in certain circumstances.

Further, the information as required to be disclosed under SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is provided in **Annexure I**. The Meeting of the Board of Directors commenced at 2:30 PM and concluded at 3:00 PM.

This is for your information and record.

Yours faithfully,
For Health X Platform Limited
(formerly known as Sastasundar Ventures Limited)

PRATAP SINGH

Digitally signed by PRATAP SINGH
DN: c=IN, o=PERSONAL, title=9767, 2.5.4.20=2a7ee0833f15369050bcb8812721eedc37eb2d969f49ca2bb966de9c83d533a7, postalCode=711204, st=West Bengal, serialNumber=6a38acf8d61293d95d818b2d95dba95f63a20723f3d90094dec69f9382fad46, cn=PRATAP SINGH
Date: 2026.02.27 15:18:15 +05'30'

Pratap Singh
Company Secretary & Compliance Officer
M. No. A24081

ANNEXURE - I

Sl. No.	Particulars	Disclosure
a)	Names of parties with whom the agreement is entered.	Health X Platform Limited (formerly Sastasundar Ventures Limited), Sastasundar Healthbuddy Limited (SHBL) and Envision India Fund.
b)	Purpose of entering into the agreement	The parties have entered into this Agreement for the purposes of recording the terms and conditions governing the relationship of the shareholders of SHBL, a material subsidiary of the Company post Envision becoming a shareholder of SHBL.
c)	shareholding, if any, in the entity with whom the agreement is executed	SHBL is the material subsidiary of the Company and Envision India Fund is the Qualified Institutional Buyer and an Independent Investor. Shareholding of SHBL, post completion of transaction is as following: Health X Platform Limited (formerly known as Sastasundar Ventures Limited) – 17,100,160 Eq. shares Rohto Pharmaceuticals Co., Ltd. – 3,562,064 Eq. shares Envision India Fund - 10,13,766 Eq. shares Total - 21,675,990 Eq. shares
d)	significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	The Tripartite Agreement, contemplates a scheme of arrangement to be undertaken between the Company and SHBL, whereby SHBL shall ultimately be merged with HealthX subject to compliance with Applicable laws. The Tripartite Agreement contemplates that the merger shall, subject to compliance with applicable laws, be undertaken in a manner such that the economic interest of Envision in HealthX after the consummation of the scheme shall remain the same as it was in SHBL prior to the merger. It is also agreed in the Tripartite Agreement that, if the scheme of arrangement resulting in merger of SHBL with the Company is not consummated, the Company shall undertake a share swap arrangement so as to ensure that Envision receives equivalent shares of HealthX in lieu of shares held in SHBL. The Board had made a disclosure regarding in-principle approval for undertaking a scheme of arrangement involving a merger of SHBL with the Company on 26.02.2026 to the stock exchanges. Envision is also entitled to nominate one director on the board of HealthX in case of any material breach or non-consummation of the merger.
e)	whether, the said parties are related to promoter/ promoter group/ group companies in any manner. If yes, nature of relationship.	The Company (HealthX) is a promoter of SHBL.

Sl. No.	Particulars	Disclosure
f)	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length".	The transaction falls within the scope of related party transactions as SHBL is a subsidiary of HealthX.
g)	In case of issuance of shares to the parties, details of issue price, class of shares issued.	Not Applicable
h)	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	Not Applicable
i)	In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a) name of parties to the agreement; b) nature of the agreement; c) date of execution of the agreement; d) details of amendment and impact thereof or reasons of termination and impact thereof.	Not Applicable

PRATAP SINGH

Digitally signed by PRATAP SINGH
DN: c=IN, o=PERSONAL, title=9787, 2.5.4.20=2a7ee0833f1536905bcb881272eedc37eb2d96f49bca0b6966b69e9c81d533a7, postalCode=711204, st=West Bengal, serialNumber=6a38acf8d61293d955d818b2d95dba95f63a2072f3df9009 4dec69f93829ad46, cn=PRATAP SINGH
Date: 2026.02.27 15:18:42 +05'30'

Date: 26-02-2026

To,
The General Manager,
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai - 400001

To,
Manager – Listing,
Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Mumbai - 400051

Ref: Scrip Code at BSE: 533259 and NSE: SASTASUNDR

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Intimation by Sastasundar Healthbuddy Limited ("SHBL"), a material subsidiary of the Company, regarding Outcome of its Board Meeting for granting in-principle approval to its restructuring process.

Dear Sir/ Madam,

Pursuant to regulation 30(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, it is hereby informed that the board of directors of Sastasundar Healthbuddy Limited ("Board or SHBL"), a material subsidiary of the Company, at its meeting held today has accorded its in-principle approval to a restructuring process (which may include a merger and/or demerger) whereby it shall ultimately merge into its holding company, Health X Platform Limited (formerly Sastasundar Ventures Limited), under a court-sanctioned scheme of arrangement ("Restructuring"). The Board is exploring the Restructuring as an option to ensure independent group structures for each of its health care and financial services business with an intent that the underlying economic interest of the shareholders of SHBL post-merger with the Company shall remain intact, however subject to the final valuation.

Please note that the in-principle approval of the Board for the Restructuring is under further evaluation and finalisation in due course. Further, the Restructuring is contingent on the closing of the transaction of sale by Mitsubishi Corporation, an existing shareholder of SHBL, of its entire shareholding to Envision India Fund, a QIB, pursuant to the share purchase agreement dated 25.02.2026 ("SPA"). A disclosure regarding the execution of the SPA has already been made by the Company on 25.02.2026 to the Stock Exchanges.

SHBL shall appoint necessary independent valuer(s) to carry out the valuation exercise and submit the report to the Board, after which the final decision on the Restructuring shall be taken. The Restructuring shall be subject to final approvals from the Board, being obtained as per applicable law, and be implemented in the next financial year, post finalisation of the accounts of the FY 25-26.

The said in-principle approval accorded by the Board is under further evaluation and finalisation by the Board in due course.

The Company received the aforesaid information from SHBL on February 26, 2026 at 1:16 PM. This is for your information and record.

Yours faithfully,
For Health X Platform Limited
(formerly known as Sastasundar Ventures Limited)

PRATAP SINGH

Digitally signed by PRATAP SINGH
DN: c=IN, o=PERSONAL, title=9767, 2.5.4.20=2a7ee0833f1536905f8cb8812721eedc37eb2d96f496ca0b6966de9c83d533a7, postalCode=711204, st=West Bengal, serialNumber=4a38acf8d61293d955d818b2d95dba95f63a207255fd90094dec69f93829ad46, cn=PRATAP SINGH
Date: 2026.02.26 15:42:21 +05'30'

Pratap Singh
Company Secretary & Compliance Officer
M. No. A24081

Date: 26-02-2026

To,
The General Manager,
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai – 400001

To,
Manager – Listing,
Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Mumbai — 400051

Ref: Scrip Code at BSE: 533259 and NSE: SASTASUNDR

Sub: Disclosure under Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding in-principle approval of Scheme of Arrangement by the Board of Directors of Health X Platform Limited (formerly known as Sastasundar Ventures Limited) – Outcome of Meeting of the Board of Directors

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), it is hereby informed that the Board, at its meeting held today on February 26, 2026, has accorded its in-principle approval for a restructuring process (which may include a merger and/or demerger) whereby its material subsidiary, i.e., Sastasundar Healthbuddy Limited ("SHBL"), will ultimately be merged into Health X Platform Limited (formerly Sastasundar Ventures Limited) ("HealthX") under a court-sanctioned scheme of arrangement ("Restructuring"). The Board is exploring the Restructuring as an option to ensure independent group structures for each of its health care and financial services business with an intent that the underlying economic interest of the shareholders of SHBL post-merger with HealthX shall remain intact, however subject to the final valuation.

Please note that the in-principle approval of the Board for the Restructuring is under further evaluation and finalisation in due course. Further, the Restructuring is contingent on the closing of the transaction of sale by Mitsubishi Corporation, an existing shareholder of SHBL, of its entire shareholding to Envision India Fund, a QIB, pursuant to the share purchase agreement dated 25.02.2026 ("SPA"). A disclosure regarding the execution of the SPA has already been made by the Company on 25.02.2026 to the Stock Exchanges.

The Company shall appoint necessary intermediaries and independent valuer(s) to carry out the valuation exercise and submit the report to the Audit Committee and the Board after which the final decision on the Restructuring shall be taken. The Restructuring shall be subject to final approvals of the Board, Audit Committee and Independent Directors being obtained as per applicable law, and be implemented in the next financial year post finalisation of the accounts of the FY 25-26.

Necessary announcements and disclosures in accordance with the SEBI Listing Regulations and other applicable laws will be made once the Board completes its evaluation and finalises the manner of Restructuring. This communication is being made by way of abundant caution to inform the market participants, and no speculation should be drawn from this communication. The Company shall communicate the development wherever necessary and required under applicable laws.

The Meeting of the Board of Directors commenced at 2:00 PM and concluded at 2:20 PM.

This is for your information and record.

Yours faithfully,

For Health X Platform Limited
(formerly known as Sastasundar Ventures Limited)

PRATAP SINGH

Digitally signed by PRATAP SINGH
DN: c=IN, o=PERSONAL, title=9767, 2.5.4.20=2a7ee0833f15369050bcb8812721eedc37eb2d96f496ca0b6966de9c83d533a7, postalCode=711204, st=West Bengal, serialNumber=6a38acf8d61293d955d818b2d95dba95f63a20725f3d90094dec69f93829ad46, cn=PRATAP SINGH
Date: 2026.02.26 14:42:58 +05'30'

Pratap Singh
Company Secretary & Compliance Officer
M. No. A24081

Date: 25-02-2026

To,
The General Manager,
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai – 400001

To,
Manager – Listing,
Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Mumbai — 400051

Ref: Scrip Code at BSE: 533259 and NSE: SASTASUNDR

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Execution of Share Purchase Agreement by Sastasundar Healthbuddy Limited, material subsidiary of the Company

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has received intimation from Sastasundar Healthbuddy Limited ("SHBL"), a material subsidiary of Health X Platform Limited (formerly known as Sastasundar Ventures Limited) ("Company"), that on February 25, 2026 a Share Purchase Agreement ("SPA") has been executed between SHBL, Mitsubishi Corporation ("Seller") and Envision India Fund ("Buyer").

Pursuant to the aforesaid SPA, the Buyer shall acquire 10,13,766 (Ten Lakh Thirteen Thousand Seven Hundred Sixty Six) Equity Shares, representing 4.68% of total issued and paid-up share capital of SHBL from the Seller, at a price of Rs. 493.21 per share, aggregating to total consideration of Rs. 49,99,99,528.86 subject to the satisfaction of the agreed terms and conditions as stipulated in the SPA.

Consequent to completion of above acquisition of shares by the buyer, the Seller shall cease to be the shareholder of the SHBL.

The Company has received the aforesaid information from SHBL on February 25, 2026 at 7:57 P.M.

Yours faithfully,

For Health X Platform Limited
(formerly known as Sastasundar Ventures Limited)

PRATAP SINGH

Digitally signed by PRATAP SINGH
DN: c=IN, o=PERSONAL, title=9767, 2.5.4.20=2a7ee0833f15369050bcb881272 1eedc37eb2d96f496ca0b6966de9c83d533a7, postalCode=711204, st=West Bengal, serialNumber=6a38acf8d61293d955d818b2d95dba95f63a2072 5f3d90094dec69f93829ad46, cn=PRATAP SINGH
Date: 2026.02.25 22:23:41 +05'30'

Pratap Singh
Company Secretary & Compliance Officer
M. No. A24081